Table 3.
Author, date | Tumor response | Complete response | Partial response | Stable disease | Progressive disease | ||
---|---|---|---|---|---|---|---|
Imaging evaluation method | Parameter evaluated | Result #pt | |||||
Xiong, 2001 [53] | US | hyperechogenicity | 21 | ||||
Xu, 2003 [54] | US | hypovascularity | 12 | ||||
Yuan, 2003 [55] | CT, US, CDFI | N/A | 36 | 8 | 28 | 0 | 4 |
Gu, 2004 [21] | CDFI | N/A | N/A | ||||
Li, 2004 [22] | CT, US,CDFI, pathological analysis only in the effective | reduction in tumor size, hyperechogenicity, blood flow decrease/disappearance | 9 | ||||
Wu, 2005 [32] | CT or MRI | tumor reduction rate (range 20–70%) | 8 | ||||
Xie, 2008 [56] | US | hyperchogenicity | 15 | ||||
Xiong, 2009 [44] | CT or MRI | absence of perfusion | 64 | ||||
Zhao, 2010 [45] | CT | RECIST | 32 | 2 | 15 | 15 | 5 |
Orsi, 2010 [57] | PET/CT, CT or MRI | focal uptake of FDG, low attenuation at the ablation site without contrast enhancement at the edges | 5 | ||||
Wang, 2011 [33] | CT | decreased enhancement | 35 | 0 | 7 | 28 | 5 |
Sung, 2011 [35] | MRI | stack model (unenhanced area) | 46 | ||||
Orgera, 2011 [58] | PET/CT or MRI, US, CT | lack of contrast and enhancement of metabolic activity | 3 | ||||
Li, 2012 [59] | US, CT | hyperechogenicity, and hypovascularity(US), tumor necrosis and reduction (CT) | 18 | ||||
Gao, 2013 [60] | CT or MRI | decrease or disappearance of blood supply in target region and circular enhancement in tumor periphery | 30 | 0 | 5 | 25 | 9 |
Anzidei, 2014 [24] | CT and MRI | changes in density and intensity, contrast enhancement, non perfused volume (at least 60%) | 6 | ||||
Sofuni, 2014 [61] | CT | WHO criteria | 26 | 0 | 4 | 22 | 4 |
Marinova, 2016a [23] | US | lack of contrast enhancement | 13 | ||||
Li YJ, 2016 [34] | MRI, CT, US | RECIST | 11 | 0 | 7 | 4 | 5 |
Li X, 2016 [49] | CT | RECIST | 16 | 1 | 15 | N/A | N/A |
Strunk, 2016 [62] | US, CT, MRI | tumor ablation rate (NPV/total volume) | 8 | ||||
Lv, 2016 [48] | CT | RECIST | 18 | 0 | 10 | 8 | 0 |
Marinova, 2016b [36] | CT and MRI | tumor volume reduction | N/A |
FDG flurodeoxyglucose, NPV non perfused volume, CDFI color doppler flow imaging, RECIST response evaluation criteria in solid tumors